CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Astrazeneca PLC (AZN) / volrustomig
Forward catalyst · AZN

volrustomig

Sponsor Astrazeneca PLC · listed as AZN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

volrustomig is a clinical-stage drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Nov 26, 2027 (day precision, medium confidence), tied to trial NCT06079671. The asset is in Phase 3 and currently recruiting, studied in Locally Advanced Cervical Cancer. It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-11-26
As disclosedNov 26, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06079671
PhasePHASE3
StatusRECRUITING
Lead sponsorAstraZeneca
Listed asAZN
Condition(s)Locally Advanced Cervical Cancer
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More AZN catalysts

Related catalysts and sponsor